We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Germany-based Boehringer Ingelheim has entered a collaboration and licensing agreement with Danish biotech company Gubra to develop new peptide compounds to treat obesity.